NICE To Recommend AZ's Lynparza After All
This article was originally published in Scrip
Executive Summary
AstraZeneca has managed to provide the necessary evidence for NICE, the health technology appraisal institute for England and Wales, to say yes to its PARP inhibitor Lynparza (olaparib) for a patient subpopulation with BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer. Earlier this year NICE looked set to reject the drug.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.